22 February 2016 - Bayer has received approval from the European Commission of Kovaltry for the treatment of hemophilia A in patients of all age groups. Kovaltry is an unmodified full-length recombinant factor VIII product, that in clinical trials has demonstrated control of bleeds, and protection from bleeds in hemophilia A patients when used prophylactically two or three times per week.

For more details, go to: http://www.news.bayer.com/baynews/baynews.nsf/id/Bayer-Receives-EU-Approval-of-Kovaltry-for-Treatment-of-Hemophilia-A?OpenDocument&sessionID=1456167537